Hercules Capital, Inc. (HTGC) - Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Hercules Capital, Inc. is an internally managed, non-diversified closed-end management investment company regulated as a Business Development Company (BDC) under the Investment Company Act of 1940. The Company focuses on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in technology and life sciences industries. As of June 30, 2024, the Company had 162.4 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Investment Income | $125.0 million | $116.2 million | $246.6 million | $221.3 million |
| Net Investment Income | $82.4 million | $75.7 million | $161.5 million | $141.2 million |
| Net Realized Gain (Loss) | ($5.8 million) | $0.2 million | $2.4 million | $8.2 million |
| Net Unrealized Appreciation (Depreciation) | ($34.7 million) | $18.9 million | ($31.1 million) | $40.0 million |
| Net Increase in Net Assets from Operations | $41.9 million | $94.8 million | $132.8 million | $189.3 million |
| Net Asset Value (NAV) per Share | $11.43 | $10.96 | $11.43 | $10.96 |
| Total Debt Outstanding | $1.76 billion | $1.57 billion | $1.76 billion | $1.57 billion |
| Cash and Cash Equivalents | $27.7 million | $61.7 million | $27.7 million | $61.7 million |
Material Changes vs. Prior Period
- Investment Portfolio Growth: Total investments at fair value increased to $3.57 billion from $3.25 billion at year-end 2023, driven by new fundings of approximately $830 million (net) in the first half of 2024.
- Unrealized Depreciation: The Company recorded a net unrealized depreciation of $31.1 million for the six months ended June 30, 2024, compared to appreciation of $40.0 million in the prior year period. This was primarily due to valuation adjustments in the debt portfolio and equity/warrant holdings.
- Realized Losses: Q2 2024 saw a net realized loss of $5.8 million, largely due to write-offs of equity and warrant investments in companies such as Proterra, Inc. and The Faction Group LLC, and debt write-offs related to Better Therapeutics, Inc. and Eigen Technologies Ltd.
- Debt Utilization: Total debt increased by approximately $192 million compared to December 31, 2023, reflecting increased usage of the MUFG and SMBC credit facilities to fund new investments.
- Non-Accrual Status: Non-accrual investments increased to 2.5% of the total portfolio at amortized cost ($92 million) from 1.0% ($31 million) at year-end 2023.
Guidance, Outlook, and Risks
- Portfolio Yield: The weighted average core yield on debt investments was 13.7% for the quarter ended June 30, 2024, down from 14.1% in the prior year quarter. The effective yield was 14.7%.
- Liquidity: As of June 30, 2024, the Company had approximately $482 million in available liquidity, including cash and available borrowing capacity under credit facilities. The Company recently received a fourth SBIC license (SBIC V) on July 9, 2024, providing access to an additional $175 million in SBA debentures.
- Dividends: The Board declared a quarterly distribution of $0.40 per share and a supplemental distribution of $0.08 per share, payable on August 20, 2024. The Company maintains a dividend reinvestment plan.
- Risks: Key risks include the performance of significant portfolio companies (e.g., Axsome Therapeutics, Phathom Pharmaceuticals, Marathon Health), which collectively represent over 30% of net assets. The Company also faces interest rate risk, with 97.4% of its debt portfolio bearing floating rates, and macroeconomic uncertainties affecting the venture capital and life sciences sectors.
Investor Verification Checklist
- Non-Accrual Trends: Verify the specific portfolio companies moved to non-accrual status and the Company's recovery strategies for the $92 million in non-accrual assets.
- Valuation Methodology: Review the Level 3 fair value inputs, particularly the hypothetical market yields used for debt investments, given the significant unrealized depreciation.
- Debt Maturity Profile: Confirm the Company's ability to refinance or repay the $275 million of debt due within the next 12 months.
- Concentration Risk: Assess the financial health of the top five portfolio companies (Axsome, Phathom, Marathon, Corium, SeatGeek) which represent significant portions of net assets.
- SBIC Licensing Impact: Monitor the drawdown timeline and utilization of the new $175 million SBIC V license received in July 2024.